PTOISBIBB. (08-03)
Approved for use through 977312086 (108-068-1-3031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
ond to a collection of information unless it contains a valid OMB control number.

	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10816224	
		Filing Date		2004-03-31	
		First Named Inventor Wesi		inger Jr., et al.	
		Art Unit		2171	
		Examiner Name	Unkn	own	
		Attorney Docket Numb	er	GRAPH-005COF	

		Remove				
Examiner Initial*	Cite No	Patent Number	Issue Date Name of Patentee of Applicant Re		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	4882474	A	1989-11-21	Anderl et al.	
	2	5671279	A	1997-09-23	Eigamai	
	3	5838903	A	1998-11-17	Blakely, III et al.	
	4	5862323	A	1999-01-19	Blakley, III et al.	
	5	5931948	A	1999-08-03	Morisawa et al.	
	6	5960411	A	1999-09-28	Hartman et al.	
	7	6029141	A	2000-02-22	Bezos et al.	
	8	6249291	B1	2001-06-19	Popp et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10816224	
Filing Date		2004-03-31	
First Named Inventor Wesi		nger Jr., et al.	
Art Unit		2171	
Examiner Name Unkn		own	
Attorney Docket Number		GRAPH-005COF	

	9	6324538	B1	2001-1	1-27	Wesinger, Jr.	et al.				
	10	6850940	B2	2005-0	2-01	Wesinger, Jr.	et al.				
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add		_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Pate of cited Docu	entee or Applicant ment	Relev		Lines wher ges or Rele	
	1										
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	blease click the Ad	d butto	n. Add		
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴ Date Name of Patentee or Applicant of cited Document Figures Appea		levant or Relevan				
	1										
If you wis	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	lease click the Add	buttor	Add		
			NO	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Examiner Cite (Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andor country where published.						T5				
	1										
If you wis	you wish to add additional non-patent literature document citation information please click the Add button Add										

	Application Number		10816224	
	Filing Date		2004-03-31	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Wesi		inger Jr., et al.	
(Not for submission under 37 CFR 1.99)	Art Unit		2171	
	Examiner Name	Unknown		
	Attorney Docket Numb	er	GRAPH-005COF	

	EXAMINER SIGNATURE		
Examiner Signature		Date Considered	
	reference considered, whether or not citation is in conformation		

1 See Kin Codes of USPTO Patent Documents at www.USPTO_GGV or MPEP 901.04. 2 Exter of thick that issued the document, by the two-lefter pated (WIPO Standard ST3.) 3 "For disputement pated counters, the endoated on the year of the register or surpressed the sense in one of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST1.6 if possible, "Applicant is to place a check mark here if Engine Imagings Permisteriors in statische."

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10816224		
Filing Date		2004-03-31		
First Named Inventor Wesi		nger Jr., et al.		
Art Unit		2171		
Examiner Name Unkn		own		
Attorney Docket Number		GRAPH-005COF		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
П	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(eV1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 178(b) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(b) (2)

_	C	 	

Fee set forth in 37 CFR 1.17	(p) has been submitted herewith.

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	
Name/Print	Timothy A. Brisson	Registration Number	44046

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, and Superiment of Commence, P. 0. Bot 1450, Alexandria, V.32.211-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.32.231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient of the patient application or patient. If you do not furnish the requested related to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may related that the patient process and/or examine your submission.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.